Released · Last reviewed
Scientific source policy and evidence hierarchy
Which sources we treat as evidence, which we refuse to treat as evidence, and how we decide how far a study's result actually stretches.
Our source hierarchy
Medical statements on this site are supported by primary or authoritative sources, in this order of preference:
- FDA drug labels, safety communications, databases and official guidance
- NIH and PubMed-indexed original research
- ClinicalTrials.gov registrations
- Peer-reviewed systematic reviews and meta-analyses
- Major professional medical guidelines
- Government sources: CDC, CMS, the NPI registry, state pharmacy and medical boards
- A provider's own pages — for that provider's prices and service claims only
What we will not treat as evidence
- Reddit and patient forums — never as evidence of price, safety, efficacy or legitimacy. They may be described as anecdotal consumer sentiment, and labelled as such.
- Affiliate comparison sites — never as proof of a medical claim, and never sufficient to mark a price Verified. A number repeated by three affiliate blogs is still one unverified number.
- Animal research — never as proof of a human clinical effect.
- Press releases — never as the sole evidence for a scientific conclusion.
- A single study — never as support for a universal claim.
- Provider marketing — never as independent proof of its own quality.
How far a result actually stretches
This is where most misuse happens, and it is not misquotation — it is extrapolation. A real result gets stretched past the population, the dose, the duration or the dosage form that was actually tested.
Every efficacy figure in the GLP-1 field comes from an FDA-approved subcutaneous injection. SURMOUNT-1 tested 5-15mg injections. STEP 1 tested a 2.4mg injection. Neither tested a compounded preparation, a 1mg microdose, or an orally disintegrating tablet. When those trial numbers appear on a page selling an ODT, evidence has been transferred across a dosage form without justification. We do not do that, and every study page we publish carries a 'what this does not prove' section for exactly this reason.
We do not invent citations
We do not invent a study, an author, a DOI, a PMID, a trial registration number or a result. Where we do not have a source, we say we do not have a source. Where a price is unverified, we label it unverified rather than publishing a plausible-looking number.
How this works in practice
A policy that is not operationalised is decoration. Here is what ours actually changes about the pages you read.
Every price carries a status. Verified means we hold a dated capture of the provider's own page. Reported — pending verification means a provider or third party reports it and we have not captured it ourselves. Evaluation in progress means we are not asserting it. We do not upgrade a price to Verified because a comparison site published it — sites in this category contradict each other routinely, and a number repeated by three affiliate blogs is still one unverified number.
Every medical claim traces to a primary source. FDA labels and guidance for regulatory status; PubMed-indexed randomised trials for efficacy; ClinicalTrials.gov for trial design. Reddit and patient forums are never used as evidence of price, safety, efficacy or legitimacy — they may be described as anecdotal sentiment, labelled as such. Animal research is never presented as proof of a human clinical effect.
Every ranking shows its arithmetic. Where a provider we have a commercial relationship with ranks well, the calculation that produced that result is printed on the page. If the arithmetic is wrong, you can see that it is wrong, and tell us.
Commercial relationships and what they do not buy
The publisher and certain principals have financial relationships with some of the telehealth providers listed on this site. That is how this publication is funded, and we state it in the footer of every page rather than burying it.
What compensation does not do: it does not change a score, a rank, an inclusion decision, or a negative finding. Providers cannot pay for placement, cannot suppress an accurate criticism, and cannot review their own page before publication. Where a commercially-related provider loses a category, we say so — a comparison in which one provider wins everything is an advertisement, and the fastest way to tell the difference is to look for the losses.
Corrections
We publish prices in a market that changes them frequently, and we will get things wrong. When we do, we correct the page, date the correction, and say what changed — we do not quietly edit a number and pretend it was always right. Both readers and providers can submit corrections with evidence, through the same process and to the same standard.
Our own record so far includes removing a set of provider prices we had sourced from a third-party comparison site and could not substantiate, and correcting brand-pricing figures that had gone stale after a manufacturer price cut. Both corrections made the site less flattering to conclusions we had already published. That is the point.
Jastreboff AM et al., N Engl J Med 2022 (NCT04184622), n=2,539. Dose-response is real: the effect rises with dose. These are FDA-APPROVED SUBCUTANEOUS INJECTION doses — they do not transfer to compounded, microdose or ODT products. Trial means are not individual promises.
Sources
- FDA — human drug compounding and GLP-1 status. fda.gov/drugs/human-drug-compounding
- Pricing and program data captured from provider sites and major publishers (Forbes Health, U.S. News), July 2026. Full records: evidence ledger.
- Methodology: price-index and affordability methodology.
The numbers behind this page
Checking the figures in this page
Every price quoted in this page comes from the programme's own pricing page and carries the date it was captured. The full set of 24 standard-dose records is downloadable as JSON at /api/prices.json, with molecule and dose class stated on every record. Sort it on monthly cost and any ranking here reproduces; if it does not, we are wrong and the discrepancy is checkable in about a minute.
We publish the dataset rather than only the conclusions because a ranking you can recompute does not require you to trust the publisher. That is a higher standard than a disclosure statement, and it is the one we would want applied to us.
Reading the price against the market
Where this sits in the market
The figures in this page sit inside a market with a measurable shape, and that shape is what makes any single price readable.
21 programmes print a price for both molecules on their own pages. Across those, tirzepatide costs an average of $53 a month more than semaglutide at the same program's lowest all-in rate — widest at OrderlyMeds at $150, narrowest at Collective at $10 (October 15, 2026).
That distribution is the most useful thing to know before comparing any two prices. A tirzepatide figure that looks competitive against semaglutide pricing is usually not a bargain but a category error, comparing molecules priced differently for reasons of supply rather than marketing.
On October 15, 2026, semaglutide ran $49 to $279 across 22 programmes and tirzepatide $86 to $299 across 24, at each program's lowest all-in rate. Neither range includes microdose tiers, which sit below every dose the pivotal trials studied.
Questions this page answers
Where do these prices come from?
Each is read from the program's own pricing page and carries its read date. The October 15, 2026 file at /api/prices.json holds 106 records, 49 of them verified standard-dose prices, with molecule, dose class and evidence status on every record.
Which tracked programs charge less than NexLife?
Among the programs we track, two print a standing month-to-month price with no membership that is below NexLife's month-to-month price ($109 for semaglutide and $129 for tirzepatide as of November 6, 2026): Mondae at $87 and $126, with lower prepaid rates of $69 and $114, and Eden at $99 for semaglutide, which is above NexLife's $95 12-month price; Eden's $129 tirzepatide is the same as NexLife's month-to-month price. Competitor prices were read on October 15, 2026. Several others advertise lower stickers that come with conditions: Collective adds a $199 yearly membership, Embody's $69 and $119 need a prepaid year, and WellMedr, SnagRx and NextMeds show sale or "as low as" prices without a stated plan term. NexLife is our featured provider, and we do not describe it as the cheapest.
Are compounded GLP-1 medicines FDA-approved?
No. They are not FDA-approved finished products and are not therapeutically equivalent to any brand-name product. FDA does not review them for safety, effectiveness or manufacturing quality before marketing.
Why do the same programmes quote two different prices?
Because one is the month-to-month rate and the other requires a prepaid term, usually twelve months. We compare programs on their lowest all-in monthly price and print the plan term beside every figure, so a rate that needs a commitment is labelled as one.